CLPTM1 Inhibitors
CLPTM1 inhibitors can be broadly described as compounds that, while not directly binding or affecting CLPTM1, modulate cellular processes that potentially have an impact on its function, expression, or cellular context. These chemical agents act on diverse cellular pathways, such as ER stress, glycolysis, protein trafficking, and degradation systems like autophagy and the proteasome.
For instance, compounds like thapsigargin induce ER stress, which can shift the cellular environment of membrane proteins like CLPTM1. Similarly, 2-Deoxyglucose, by inhibiting glycolysis, can influence the metabolic state of cells, potentially impacting proteins associated with cellular stress responses or metabolic adaptations. Another intriguing component is the proteostatic machinery – using agents like MG-132 or Eeyarestatin I, one can influence protein turnover, providing insights into the stability and degradation pathways of proteins like CLPTM1.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
An endoplasmic reticulum (ER) stress inducer. Since CLPTM1 is a membrane protein that may have some roles in ER, influencing ER stress can alter the environment where CLPTM1 operates. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
A glycosylation inhibitor. If CLPTM1 undergoes post-translational modifications like glycosylation, tunicamycin can impact its functional state or expression. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
An inhibitor of glycolysis. If CLPTM1's function or expression is tied to metabolic states of the cell, influencing glycolysis can indirectly modulate the protein's cellular context. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
An ionophore that disrupts Golgi function. If CLPTM1's trafficking or processing involves the Golgi apparatus, monensin can influence its cellular fate. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
An inhibitor of vacuolar-type H+-ATPase, affecting endosomal functions. If CLPTM1 has roles in endosomal processes, this compound can modulate its functional context. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor. If CLPTM1 turnover is associated with ubiquitin-proteasome system, MG-132 can influence its degradation rate or functional state. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule disrupting agent. If CLPTM1's trafficking or cellular localization depends on microtubule network, nocodazole can influence its spatial distribution. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A non-competitive inhibitor of dynamin, affecting endocytosis. If CLPTM1 undergoes endocytic recycling or its levels are controlled via endocytosis, dynasore can modulate its cellular levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
An inhibitor of protein biosynthesis. If there's a need to study CLPTM1 protein synthesis rate or its new expression, cycloheximide can halt new protein production, indirectly influencing its levels. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
A γ-secretase inhibitor. If CLPTM1 processing involves proteolytic cleavage by γ-secretase, DAPT can influence its maturation or functional state. | ||||||